A randomized phase II trial of S-1-oxaliplatin versus capecitabine- oxaliplatin in advanced gastric cancer

Gun Min Kim, Hei Cheul Jeung, Sun Young Rha, Hyo Song Kim, Inkyung Jung, Byung Ho Nam, Kyung Hee Lee, Hyun Cheol Chung

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Purpose: S-1 or capecitabine plus oxaliplatin are considered active and tolerable in gastric cancer patients. We conducted a randomized phase II trial in gastric cancer patients to compare the activity and safety of these combinations. Methods: The patients received S-1 at 80 mg/m 2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the S-1/oxaliplatin (SOX) arm, and capecitabine at 2000 mg/m 2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the capecitabine/oxaliplatin (CAPOX) arm. Oxaliplatin 130 mg/m 2 was administered every 3 weeks in both arms. Results: One hundred twenty-nine patients were randomly assigned to SOX (N = 65) or CAPOX (N = 64). The median time to progression and the overall survival were 6.2 and 12.4 months with SOX, respectively; and 7.2 and 13.3 months with CAPOX, respectively. The overall response rates were 40% and 44% for SOX and CAPOX, respectively. The most frequent grade 3 or 4 toxicities were thrombocytopenia (15.4%) for SOX and neutropenia (18.8%) for CAPOX. The median time to 10% deteriorations in global health scores was similar in both arms (SOX, 4.3 months, CAPOX, 4.9 months). Conclusion: Both the SOX and CAPOX regimens were equally active and well tolerated in advanced gastric cancer patients.

Original languageEnglish
Pages (from-to)518-526
Number of pages9
JournalEuropean Journal of Cancer
Volume48
Issue number4
DOIs
Publication statusPublished - 2012 Mar 1

Fingerprint

oxaliplatin
Stomach Neoplasms
Capecitabine

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Gun Min ; Jeung, Hei Cheul ; Rha, Sun Young ; Kim, Hyo Song ; Jung, Inkyung ; Nam, Byung Ho ; Lee, Kyung Hee ; Chung, Hyun Cheol. / A randomized phase II trial of S-1-oxaliplatin versus capecitabine- oxaliplatin in advanced gastric cancer. In: European Journal of Cancer. 2012 ; Vol. 48, No. 4. pp. 518-526.
@article{69b26327ce9b411eb0e2f596afeb666c,
title = "A randomized phase II trial of S-1-oxaliplatin versus capecitabine- oxaliplatin in advanced gastric cancer",
abstract = "Purpose: S-1 or capecitabine plus oxaliplatin are considered active and tolerable in gastric cancer patients. We conducted a randomized phase II trial in gastric cancer patients to compare the activity and safety of these combinations. Methods: The patients received S-1 at 80 mg/m 2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the S-1/oxaliplatin (SOX) arm, and capecitabine at 2000 mg/m 2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the capecitabine/oxaliplatin (CAPOX) arm. Oxaliplatin 130 mg/m 2 was administered every 3 weeks in both arms. Results: One hundred twenty-nine patients were randomly assigned to SOX (N = 65) or CAPOX (N = 64). The median time to progression and the overall survival were 6.2 and 12.4 months with SOX, respectively; and 7.2 and 13.3 months with CAPOX, respectively. The overall response rates were 40{\%} and 44{\%} for SOX and CAPOX, respectively. The most frequent grade 3 or 4 toxicities were thrombocytopenia (15.4{\%}) for SOX and neutropenia (18.8{\%}) for CAPOX. The median time to 10{\%} deteriorations in global health scores was similar in both arms (SOX, 4.3 months, CAPOX, 4.9 months). Conclusion: Both the SOX and CAPOX regimens were equally active and well tolerated in advanced gastric cancer patients.",
author = "Kim, {Gun Min} and Jeung, {Hei Cheul} and Rha, {Sun Young} and Kim, {Hyo Song} and Inkyung Jung and Nam, {Byung Ho} and Lee, {Kyung Hee} and Chung, {Hyun Cheol}",
year = "2012",
month = "3",
day = "1",
doi = "10.1016/j.ejca.2011.12.017",
language = "English",
volume = "48",
pages = "518--526",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "4",

}

A randomized phase II trial of S-1-oxaliplatin versus capecitabine- oxaliplatin in advanced gastric cancer. / Kim, Gun Min; Jeung, Hei Cheul; Rha, Sun Young; Kim, Hyo Song; Jung, Inkyung; Nam, Byung Ho; Lee, Kyung Hee; Chung, Hyun Cheol.

In: European Journal of Cancer, Vol. 48, No. 4, 01.03.2012, p. 518-526.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A randomized phase II trial of S-1-oxaliplatin versus capecitabine- oxaliplatin in advanced gastric cancer

AU - Kim, Gun Min

AU - Jeung, Hei Cheul

AU - Rha, Sun Young

AU - Kim, Hyo Song

AU - Jung, Inkyung

AU - Nam, Byung Ho

AU - Lee, Kyung Hee

AU - Chung, Hyun Cheol

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Purpose: S-1 or capecitabine plus oxaliplatin are considered active and tolerable in gastric cancer patients. We conducted a randomized phase II trial in gastric cancer patients to compare the activity and safety of these combinations. Methods: The patients received S-1 at 80 mg/m 2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the S-1/oxaliplatin (SOX) arm, and capecitabine at 2000 mg/m 2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the capecitabine/oxaliplatin (CAPOX) arm. Oxaliplatin 130 mg/m 2 was administered every 3 weeks in both arms. Results: One hundred twenty-nine patients were randomly assigned to SOX (N = 65) or CAPOX (N = 64). The median time to progression and the overall survival were 6.2 and 12.4 months with SOX, respectively; and 7.2 and 13.3 months with CAPOX, respectively. The overall response rates were 40% and 44% for SOX and CAPOX, respectively. The most frequent grade 3 or 4 toxicities were thrombocytopenia (15.4%) for SOX and neutropenia (18.8%) for CAPOX. The median time to 10% deteriorations in global health scores was similar in both arms (SOX, 4.3 months, CAPOX, 4.9 months). Conclusion: Both the SOX and CAPOX regimens were equally active and well tolerated in advanced gastric cancer patients.

AB - Purpose: S-1 or capecitabine plus oxaliplatin are considered active and tolerable in gastric cancer patients. We conducted a randomized phase II trial in gastric cancer patients to compare the activity and safety of these combinations. Methods: The patients received S-1 at 80 mg/m 2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the S-1/oxaliplatin (SOX) arm, and capecitabine at 2000 mg/m 2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the capecitabine/oxaliplatin (CAPOX) arm. Oxaliplatin 130 mg/m 2 was administered every 3 weeks in both arms. Results: One hundred twenty-nine patients were randomly assigned to SOX (N = 65) or CAPOX (N = 64). The median time to progression and the overall survival were 6.2 and 12.4 months with SOX, respectively; and 7.2 and 13.3 months with CAPOX, respectively. The overall response rates were 40% and 44% for SOX and CAPOX, respectively. The most frequent grade 3 or 4 toxicities were thrombocytopenia (15.4%) for SOX and neutropenia (18.8%) for CAPOX. The median time to 10% deteriorations in global health scores was similar in both arms (SOX, 4.3 months, CAPOX, 4.9 months). Conclusion: Both the SOX and CAPOX regimens were equally active and well tolerated in advanced gastric cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84862820321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862820321&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2011.12.017

DO - 10.1016/j.ejca.2011.12.017

M3 - Article

C2 - 22243774

AN - SCOPUS:84862820321

VL - 48

SP - 518

EP - 526

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 4

ER -